ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Appropriations: NIH Professional Needs Budget Gains Attention

March 14, 1997

Group Chairs: Research In “Crisis” ASCO Says NCTN Budgets Cut By 40 Percent, Warns of “Dangerous Disruption of Cancer Care”

April 4, 2014

FDA Approves New Drug for Advanced Kidney Cancer

May 25, 2007

ACS Research Budget Over $82 Million

July 17, 1987

In Brief: DTP Combines Two Branches; Robert Cooper Names DCPC Board Chairman Weicker Receives MSK Award

June 28, 1985

FDA Deputy Commissioner Gottlieb To Return To AEI.

December 15, 2006